(thirdQuint)Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec in Healthy Toddlers.

 The study is an extension of the primary vaccination study 711202/001 (MenC-TT-001).

 It comprises 5 groups: 4 parallel groups of toddlers vaccinated in study 711202/001 (group vaccinated with Meningitec cent is control group 1) and 1 group of naive subjects (no previous vaccination against MenC disease, control group 2).

 All subjects receive 1/5th dose Mencevax cent ACWY and a concomitant dose of Infanrix hexa(R).

 2 blood samples: prior to and 1 month after vaccination.

.

 Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec in Healthy Toddlers@highlight

The purpose of this booster vaccination study is to evaluate the persistence and immune memory induced by a three-dose primary vaccination course with GSK Biologicals' MenC-TT (Neisseria meningitidis group C polysaccharide-tetanus toxoid) and GSK Biologicals' Hib-MenC-TT (Haemophilus influenzae type b-MenC-TT) or Meningitec cent vaccines in healthy toddlers aged 12-15 months by giving them a 1/5th dose of Mencevax cent ACWY.

